Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 20, 2011 Charly Travers	Are These the Rights You're Looking for? Consider the contingent value rights of these pharma stocks, which entitle the owner to receive cash payments if certain performance milestones are met in the future.
The Motley Fool September 20, 2011 Jim Royal	A Hidden Opportunity for Stock Riches Here are two examples of how special situations worked recently with CVR Partners LP and Frontier Communications.
The Motley Fool February 17, 2011 Brian Orelli	What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate.
The Motley Fool July 14, 2011 David Lee Smith	Another Special Situation Within Big Oil Conoco's plans for a downstream spinoff just might benefit its shareholders.
The Motley Fool December 13, 2010 Brian Orelli	Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price.
The Motley Fool July 18, 2011 Jim Royal	2 Special Situations I'm Watching Closely Keep an eyeball on these spinoffs: ConocoPhillips... Ralcorp...
The Motley Fool July 12, 2011 Isac Simon	Why Ratings Agencies Are Wrong About Marathon Oil The upstream company is undervalued, and it will be only a matter of time before Mr. Market realizes the huge potential.
Chemistry World October 5, 2010 Andrew Turley	Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board.
The Motley Fool August 30, 2010 Ryan McBride	Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams.
The Motley Fool October 4, 2010 Ryan McBride	Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share.
The Motley Fool September 13, 2010 Brian Orelli	When All Else Fails, Sell! Genzyme has no other choice.
The Motley Fool October 31, 2008 David Lee Smith	Give This Marathon a Run Solid operating numbers and interesting deepwater prospects could propel Marathon Oil.
The Motley Fool February 4, 2008 David Lee Smith	Unrefined Results at Marathon Marathon Oil manages to lose almost all of its downstream earnings in the final quarter of 2007.
The Motley Fool January 18, 2005 David Gardner	The CEO Behind Costco A discussion with Costco's president and CEO, Jim Sinegal on his holiday predictions, stock performance, and his management style.
The Motley Fool August 2, 2007 David Lee Smith	A Busy-Bee Week for Marathon Marathon Oil management may be panting as it completes this week. There has been the acquisition of a Canadian Oil Sands company, and the settlement of a price-manipulation case.
The Motley Fool July 26, 2010 Ryan McBride	How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis
The Motley Fool February 11, 2005 David Gardner	The Future of Starbucks Starbucks' CEO designate, Jim Donald, talk about the company's prospects. This is the fifth of five parts.
The Motley Fool July 26, 2010 Brian Orelli	Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete?
The Motley Fool October 20, 2011 John Reeves	5 Banks That Will Let You Sleep at Night Look to our northern neighbors for some reliable banking investments.
The Motley Fool October 21, 2010 Brian Orelli	Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track.
The Motley Fool November 24, 2010 Brian Orelli	Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant.
The Motley Fool July 16, 2010 Eric Bleeker	Buy, Sell, or Hold Frontier Communications? Should dividend-focused investors be looking to Frontier as an all-star candidate for their portfolio? Is a dividend of this size sustainable? To discern this, here's a list of reasons to buy, sell, or hold Frontier Communications.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
The Motley Fool August 27, 2008 David Lee Smith	Big Oil Becoming Less Big ConocoPhillips' discloses that it likely will sell its remaining 600 company-owned gasoline stations to PetroSun West.
The Motley Fool November 14, 2011 Abantika Chatterjee	Can a Leaner Marathon Hold Its Ground? Mixed feelings about Marathon Oil's third-quarter earnings.
The Motley Fool February 3, 2011 David Lee Smith	Avoid Marathon Oil Wait at least for a completed Marathon restructuring before joining the race.
The Motley Fool February 7, 2005 David Gardner	Starbucks' Success Recently, Starbucks' CEO designate, Jim Donald, talked about the company's prospects. This is the first of five parts.
The Motley Fool June 16, 2009 Brian Orelli	Going Viral, but Not in a Good Way Genzyme's manufacturing problems with viruses underscore the complexity of manufacturing biologic drugs compared to small molecule drugs.
The Motley Fool January 13, 2011 April Taylor	Corporate Spinoffs -- 2011's Hot Trend Breaking up can be good.
The Motley Fool August 8, 2011 Andrew Dominguez	Big Oil Outlook: Major Oil Stocks With Bullish Options Sentiment What does the future look like for big oil?
The Motley Fool September 23, 2010 Ryan McBride	Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.
The Motley Fool February 10, 2005 David Gardner	Smart Decisions, Expensive Mistakes Starbucks' CEO designate, Jim Donald, talked about the company's prospects. This is the fourth of five parts.
The Motley Fool January 21, 2005 David Gardner	What Would Costco's CEO Do? Completing this four-part interview, Costco's president and CEO, Jim Sinegal talks about some of the challenges his company faces as well as strategies for the future.
The Motley Fool July 22, 2011 Dan Dzombak	Profit From 3 Big Energy Spinoffs The energy industry has been home to a few spinoffs this year and more are in the works over the next few months.
The Motley Fool August 30, 2010 Jordan DiPietro	How Safe Are Marathon Oil's Dividends? Evaluating the sustainability of dividend payments.
The Motley Fool February 16, 2005 David Gardner	The Flower Power of Family Recently, 1-800-Flowers.com's CEO, Jim McCann, talked about the company's products and prospects. This is the third of three parts.
The Motley Fool January 19, 2005 David Gardner	Costco's Learning Curve In this second of a four-part interview with Costco CEO Jim Sinegal, the discussion turns to class action lawsuits and retailing funeral services.
The Motley Fool February 20, 2007 Brian Lawler	Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead.
BusinessWeek January 17, 2005 Gene G. Marcial	Marathon's Bright Flame Although Marathon Oil has trailed its peers amid rising crude-oil prices, some pros say it's the play for the long run.
The Motley Fool July 12, 2006 Brian Lawler	Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share.
The Motley Fool January 5, 2010 Brian Orelli	A Deal Manufactured by Necessity Genzyme gets some help from a new friend.
The Motley Fool August 4, 2009 David Lee Smith	Marathon Outruns the Competition While its earnings slid 47%, Marathon finished in first place in one category.
The Motley Fool December 20, 2010 Roger Friedman	2 Awful Companies That Will Make You Money Jim Gillies loves awful companies. They've made him a lot of money over his investing career.
The Motley Fool November 21, 2006 Selena Maranjian	ExxonMobil: It's Not So Bad Investors, before you write off a company like ExxonMobil, or any other firm that seems like it hasn't surged or split lately for you, dig deeper.
The Motley Fool October 22, 2009 Brian Orelli	The Gift That Keeps on Giving Genzyme's manufacturing issues just won't go away. Four months after the company announced that it had shut down a manufacturing plant because of viral contamination, its stock is still dealing with the aftermath.
The Motley Fool October 28, 2010 Brian Orelli	This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37.
The Motley Fool April 20, 2006 John Bluis	Investors Jump Ship at Genzyme Clearly, Genzyme continues to invest in its business for the long term. That's the type of approach that can create a steady stream of market-beating returns for investors if they're willing to trust management.
The Motley Fool September 11, 2010 Luke Timmerman	Genzyme Cutting 1,000 Jobs Over Next 15 Months The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce.
The Motley Fool June 17, 2010	How to Play Deflation Analysts Jim Royal and Anand Chokkavelu talk about the prospect of deflation and a strategy for dealing with it.
The Motley Fool October 26, 2011 Brian Stoffel	5 Stocks Our Experts Are Buying Now An update on our Rising Star portfolios, with five of the most recent buys by our analysts, along with the thesis behind their purchases.